GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzymatica AB (XSAT:ENZY) » Definitions » Gross Profit

Enzymatica AB (XSAT:ENZY) Gross Profit : kr30.38 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Enzymatica AB Gross Profit?

Enzymatica AB's gross profit for the three months ended in Mar. 2024 was kr6.46 Mil. Enzymatica AB's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was kr30.38 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Enzymatica AB's gross profit for the three months ended in Mar. 2024 was kr6.46 Mil. Enzymatica AB's Revenue for the three months ended in Mar. 2024 was kr9.42 Mil. Therefore, Enzymatica AB's Gross Margin % for the quarter that ended in Mar. 2024 was 68.53%.

Enzymatica AB had a gross margin of 68.53% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Enzymatica AB was 74.33%. The lowest was 58.13%. And the median was 65.44%.

Warning Sign:

Enzymatica AB gross margin has been in long-term decline. The average rate of decline per year is -4%.


Enzymatica AB Gross Profit Historical Data

The historical data trend for Enzymatica AB's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymatica AB Gross Profit Chart

Enzymatica AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.90 75.96 33.35 28.45 31.86

Enzymatica AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.94 5.48 8.28 10.16 6.46

Competitive Comparison of Enzymatica AB's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymatica AB's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Gross Profit distribution charts can be found below:

* The bar in red indicates where Enzymatica AB's Gross Profit falls into.



Enzymatica AB Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Enzymatica AB's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=50.904 - 19.041
=31.86

Enzymatica AB's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=9.422 - 2.965
=6.46

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr30.38 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Enzymatica AB's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=6.46 / 9.422
=68.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Enzymatica AB  (XSAT:ENZY) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Enzymatica AB had a gross margin of 68.53% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Enzymatica AB Gross Profit Related Terms

Thank you for viewing the detailed overview of Enzymatica AB's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzymatica AB (XSAT:ENZY) Business Description

Traded in Other Exchanges
Address
Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.

Enzymatica AB (XSAT:ENZY) Headlines

From GuruFocus

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson 12-07-2015

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi 12-20-2016

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon 07-01-2016